Description of Clinical Expertise

Dr. Dember has more than 25 years of experience as a general nephrologist and has internationally-recognized expertise in the systemic amyloidoses, a group of rare disorders that often affect the kidneys. She has been involved in the development of novel treatments for AL and AA amyloidosis, and is a member of the University of Pennsylvania multidisciplinary amyloidosis program that evaluates and treats patients with all types of amyloidosis and paraprotein disorders.

Description of Other Expertise

Dr. Dember is a Deputy Editor of the American Journal of Kidney Diseases and has served on multiple NIH grant review panels and committees of the American Society of Nephrology. She is the Director of the CCEB Certificate Program in Clinical Research and is a mentor to early stage investigators.

Description of Research Expertise

Dr. Dember conducts patient-oriented research including mechanistic studies and clinical trials in chronic kidney disease and end-stage renal disease (ESRD). She has held leadership roles in several multicenter clinical trials and observational studies including the Dialysis Access Consortium, the Hemodialysis Fistula Maturation Study, the Hemodialysis Novel Therapies Consortium, the Chronic Renal Insufficiency Cohort study, and the HOPE Consortium trial, all funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). As the Principal Investigator for the NIH Time to Reduce Mortality in End-Stage Renal Disease trial (TiME), Dr. Dember played an important role in introducing to the Nephrology community large pragmatic trials embedded in clinical care delivery, an effort that she is continuing as a Co-Investigator for the NIDDK HiLo trial and as Multiple PI for the PCORI-funded SMaRRT-HD Study. She is currently serving as the Principal Investigator for the Data Coordinating Center for the HOPE Trial, the CRIC Study, and the SMaRRT-HD Study.